BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30100082)

  • 1. Imaging Tumor Proliferation in Breast Cancer: Current Update on Predictive Imaging Biomarkers.
    Elmi A; McDonald ES; Mankoff D
    PET Clin; 2018 Jul; 13(3):445-457. PubMed ID: 30100082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Imaging and Precision Medicine in Breast Cancer.
    Chudgar AV; Mankoff DA
    PET Clin; 2017 Jan; 12(1):39-51. PubMed ID: 27863565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted nuclear imaging of breast cancer: status of radiotracer development and clinical applications.
    Kong FL; Kim EE; Yang DJ
    Cancer Biother Radiopharm; 2012 Mar; 27(2):105-12. PubMed ID: 21877909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using nuclear medicine imaging in clinical practice: update on PET to guide treatment of patients with metastatic breast cancer.
    Clark AS; McDonald E; Lynch MC; Mankoff D
    Oncology (Williston Park); 2014 May; 28(5):424-30. PubMed ID: 25004657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of PET/CT in diagnosis and treatment of breast cancer -- review of present knowledge and perspectives for future research].
    Madaras B; Horváth Z; Láng I; Kásler M; Borbély K
    Magy Onkol; 2012 Mar; 56(1):23-9. PubMed ID: 22403759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to therapy in breast cancer.
    Avril N; Sassen S; Roylance R
    J Nucl Med; 2009 May; 50 Suppl 1():55S-63S. PubMed ID: 19380410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Strategies for Breast Cancer Imaging: New Imaging Agents to Guide Treatment.
    McDonald ES; Mankoff DA; Mach RH
    J Nucl Med; 2016 Feb; 57 Suppl 1():69S-74S. PubMed ID: 26834105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18FDG-PET for early prediction of complete response to lapatinib and capecitabine in HER2-positive metastatic breast cancer: a case report.
    Riccardi F; Mocerino C; Barbato C; Vitale MG; Carrillo G; Trunfio M; Minelli S; Cartenì G
    Tumori; 2013; 99(6):257e-60e. PubMed ID: 24503798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
    Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.
    Avril S; Muzic RF; Plecha D; Traughber BJ; Vinayak S; Avril N
    J Nucl Med; 2016 Feb; 57 Suppl 1(Suppl 1):34S-9S. PubMed ID: 26834099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET Imaging of Breast Cancer: Role in Patient Management.
    Lebron L; Greenspan D; Pandit-Taskar N
    PET Clin; 2015 Apr; 10(2):159-95. PubMed ID: 25829085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography and neoadjuvant therapy of breast cancer.
    Cochet A; Generali D; Fox SB; Ferrozzi F; Hicks RJ
    J Natl Cancer Inst Monogr; 2011; 2011(43):111-5. PubMed ID: 22043055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast PET/MR Imaging.
    Melsaether A; Moy L
    Radiol Clin North Am; 2017 May; 55(3):579-589. PubMed ID: 28411681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Usefulness of 18F-FDG-PET in breast cancer imaging].
    Tayama K; Toh U; Fujii T; Shirouzu K; Kaida Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():373-8. PubMed ID: 17679209
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
    He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
    PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multiparametric and molecular imaging of breast tumors with MRI and PET/MRI].
    Pinker K; Marino MA; Dr Meyer-Baese A; Helbich TH
    Radiologe; 2016 Jul; 56(7):612-21. PubMed ID: 27364727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular imaging using PET and SPECT for identification of breast cancer subtypes.
    Liu H; Chen Y; Wu S; Song F; Zhang H; Tian M
    Nucl Med Commun; 2016 Nov; 37(11):1116-24. PubMed ID: 27438531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.